- $27.52m
- $39.67m
- $37.06m
CytoSorbents 2025 revenue rises, net loss narrows
CytoSorbents' prelim 2025 revenue misses estimates
Blood purification firm CytoSorbents Q3 revenue misses estimates
Brief: Cytosorbents Provides Drugsorb-Atr Regulatory Update
Brief: Cytosorbents Updates U.S. FDA Regulatory Status Of Drugsorb-Atr
Cytosorbents Corp reports results for the quarter ended June 30 - Earnings Summary
Medical devices firm CytoSorbents Q2 revenue beats estimates
Cytosorbents Corp expected to post a loss of 5 cents a share - Earnings Preview
Brief: Cytosorbents Provides U.S. FDA And Health Canada Regulatory Update For Drugsorb-Atr
Brief: Cytosorbents Files Appeal With U.S. FDA For Supervisory Review Of De Novo Request
Cytosorbents Corp expected to post a loss of 7 cents a share - Earnings Preview
Brief: Cytosorbents Appoints Thomas Shannon As Vice President Of Marketing For North America
Brief: Cytosorbents Corp - Extends Expiration Date Of Series B Right Warrants To June 10, 2025 - SEC Filing
Brief: Cytosorbents Reports Fourth Quarter And Full Year 2024 Financial Results And Recent Business Highlights
Brief: Cytosorbents Corp - On March 25, Determined To Restate 2023 Financial Statements Due To Misstatements - SEC Filing
Cytosorbents Corp reports results for the quarter ended December 31 - Earnings Summary
Cytosorbents Corp expected to post a loss of 6 cents a share - Earnings Preview
Cytosorbents Corp expected to post a loss of 6 cents a share - Earnings Preview
Brief: Cytosorbents Corp Reaffirms Preliminary Financial Expectations For Q4 And FY 2024